Phase I study using pulverized curcumin for pancreatic/biliary tract cancer patients who get resistant to gemcitabine-based chemotherapy

Phase I study using pulverized curcumin for pancreatic/biliary tract cancer patients who get resistant to gemcitabine-based chemotherapy - Phase I study using pulverized curcumin for pancreatic/biliary tract cancer patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002950

Enrollment

Registered

2010-12-01

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic/biliary tract cancer patients who get resistant to gemcitabine-based chemotherapy

Interventions

pulverized curcumin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have histologically or radiologically comfirmed pancreatic/biliary tract cancer 2. Patients who get resistant to gemcitabine based chemotherapy 3. Age >/=20 4. ECOG performance status </=2 5. Adequate oral intake 6. Adequate organ and bone marrow function 7. Provided written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with active interstitial pneumonia or pulmonary fibrosis 2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months 3. Patients with severe infection 4. Patients with severe drug allergy 5. Patients with other serious comorbid diseases 6. Pregnant women or patients who wish pregnanct 7. Patients with mental diseases 8. Patients who are judged inappropriate for the entry into the study by the investigator

Design outcomes

Primary

Measure	Time frame
Phase I; To find a recommended dose of pulverized curcumin	—

Countries

Japan

Contacts

Public ContactMasashi Kanai

Kyoto University Hospital Outpatient Oncology Unit

075-751-4770

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026